Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
August Aug 30: Outlook Therapeutics lost nearly three-quarters of its market share after the FDA declined to approve ONS-5010, an investigational ophthalmic formulation of the cancer drug bevacizumab being developed for wet age-related macular degeneration (AMD)
However, the choice of compounding pharmacy is a critical factor that determines the safety and quality of the medication
Clinical oversight required: Dosage adjustments, reconstitution, and injection technique should always be guided by a licensed provider
The solution should be clear and colorless when fully dissolved
US$ 29.03
US$ 27.68
US$ 21.91
US$ 29.50
US$ 28.60
US$ 29.90
US$ 20.39
US$ 21.88
